References
- Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982;37:79–82.
- Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992;166:1986–1992.
- Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpreg-nane progestin (trimegestone). Gynecol Endocrinol 1999;13: 316–326.
- Weiderpass E, Adami H-0, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–1137.
- Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110–1116.
- Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endo-metrium. N Engl J Med 1981;305:1599–1605.
- Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458–461.
- Whitehead MI. Prevention of endometrial abnormalities. Acta Obstet Gynecol Scand Suppl 1986;134:81–91.
- Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Pre-marin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213–1223.
- Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmeno-pausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–375.
- Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000;CD000402.
- Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg L-G. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991;164:47–52.
- Pornel B, Spielmann D, Trimegestone 302 Study Group. A study of the control of climacteric symptoms in postmeno-pausal women following sequential regimens of 1 mg 17)3-estradiol and trimegestone compared with a regimen contain-ing 1 mg estraiol valerate and norethisterone over a 2-year period. Gynecol Endocrinol 2005;21 (2):74–81.
- Nasri MN CGJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989;96:1333–1338.
- Committee for Proprietary Medicinal Products. Points to consider on hormone replacement therapy. London: Eur-opean Agency for the Evaluation of Medicinal Products; 1997.
- Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686–692.
- Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245–251.
- Erkkola R, Kumento U, Lehmuskoski S, Matilda L, Mustonen M. No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen—progestogen therapy after five years. J Br Menopause Soc 2004;10:9–13.